Oncology Is Booming But Cost Outlook Is Grim, IMS Says
The cost of oncology therapeutics and supportive care drugs grew 11.5% to $107bn in 2015 at constant exchange rates and is expected to reach $150bn globally in 2020, according to a new IMS report.
You may also be interested in...
Industry's Rebate Arms Race: Securing Market Access At A Cost
Rebates have become industry's go-to for securing market access for drugs in competitive therapeutic areas in the US. But as payers push back, competitive rebating is intensifying and eating into the bottom line.
Benefit vs cost: ASCO unveils cancer drug 'value' tool
The American Society of Clinical Oncology (ASCO) asked the question "What is a cancer drug's true value?" and in four very specific treatment situations the organization's Value in Cancer Care Task Force supplied an answer: It depends.
Takeda’s High-Dose TYK2 Data Could Set It Apart In Psoriasis
Safety and efficacy data show that as long as Takeda can execute effectively on a Phase III program for TAK-279, the company should be well positioned in the oral psoriasis market.